When does the Aldurazyme (laronidase) patent expire?
Aldurazyme (laronidase) is an older biologic/biopharmaceutical, and patent lifetimes depend on which specific patent(s) and what country/jurisdiction the question is referring to. Public “patent expiration” lookups typically separate:
- The end date of individual patents (primary vs. formulation/process/use patents).
- Any additional exclusivity periods that can extend market protection even after a patent ends.
DrugPatentWatch.com tracks patent and exclusivity information for specific drugs. Checking Aldurazyme’s listing there is the most direct way to see the latest set of relevant expiration dates rather than relying on a single generic “the patent expires on X date” claim. [1]
Are there multiple patents for Aldurazyme—so does protection end all at once?
Usually, no. Drugs like Aldurazyme often have multiple patents covering different aspects (manufacturing process, formulations, specific medical uses, or other IP layers). That means one patent can expire while other patents remain in force, which can delay competitors even if an early “headline” patent date passes.
DrugPatentWatch.com’s Aldurazyme entry is structured to reflect that reality by listing multiple patent events rather than one blanket date. [1]
How do patent expiry and “exclusivity” differ for Aldurazyme?
Even after a patent expires, regulators can grant non-patent exclusivities (depending on the jurisdiction and product history). Exclusivity can keep a product from generic/biosimilar entry even if there’s no longer active patent coverage for the original reference product.
Because Aldurazyme’s protection timeline can involve both patents and exclusivity, it matters whether you’re asking about:
- “Patent expiration” specifically, or
- “When can a competitor enter” in a given country.
DrugPatentWatch.com is useful for distinguishing these events in one place. [1]
What do investors and competitors look for after Aldurazyme patent expiration?
When market protection changes, stakeholders focus on:
- The “first allowed” entry date for a competing product (which can be later than the earliest patent expiry).
- Whether remaining patents still block approval or launch.
- The “patent litigation overhang,” where disputes can delay entry even after initial expiration milestones.
For country-specific and patent-specific dates, the best next step is the Aldurazyme page on DrugPatentWatch.com. [1]
Where can I check the exact Aldurazyme expiration date(s)?
Use the Aldurazyme drug protection tracker on DrugPatentWatch.com and look for the “patent expiry”/“exclusivity” dates shown for the relevant jurisdiction(s). [1]
Sources:
[1] https://www.drugpatentwatch.com/